Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The June issue includes Reviews on the role of macronutrients in obesity and young-onset type 2 diabetes mellitus, as well as a Perspective on interventions for preventing fractures in postmenopausal women with osteoporosis.
Image: Dermal adipocyte staining in the skin of a 35-day-old ‘adipochaser’ mouse. Image supplied by Zhuzhen Zhang and Philipp Scherer, Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, USA. Cover design: Jennie Vallis.
Type 2 diabetes mellitus and hypertension are the most common comorbidities in patients with coronavirus infections. Emerging evidence demonstrates an important direct metabolic and endocrine mechanistic link to the viral disease process. Clinicians need to ensure early and thorough metabolic control for all patients affected by COVID-19.
Available evidence demonstrates a crosstalk between the renin–angiotensin and the parathyroid hormone–vitamin D systems. A new study suggests that vitamin D supplementation can lower systolic blood pressure and plasma aldosterone levels in patients with primary aldosteronism.
This Review summarizes the process involved in the metabolism of macronutrients (carbohydrates, lipids and proteins) with a focus on the physiological and neuroendocrine aspects. The associations between macronutrients and obesity are also discussed in the context of factors such as genetics and the microbiome composition.
Young-onset type 2 diabetes mellitus (T2DM) diagnosed in people aged <40 years has a more rapid disease course that later-onset T2DM. This Review discusses the current and future burden of young-onset T2DM in different populations and highlights the associations of young-onset T2DM with premature mortality and morbidity.
Osteoporosis interventions are currently recommended in a small proportion of postmenopausal women, of whom ~50% will experience bone fracture. This Perspectives proposes that broader use of generic bisphosphonates would result in reductions in total fracture numbers and suggests that the current bone density definition of osteoporosis requires reappraisal.